The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
Open accessAbstract
We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age >/=70 and performance status 0-2, or age <70 and PS 3. The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(-2) IV on days 1-3. The SPE arm received cisplatin 25 mg m(-2) IV on days 1-3 and etoposide 80 mg m(-2) IV on days 1-3. Both regimens were given with granulocyte colony-stimulating factor support in a 21-28 day cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade 3-4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P=0.54). Palliation scores were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk-benefit balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Carboplatin is routinely used to treat non-small cell lung cancer.
“In addition, carboplatin is routinely used to treat non-small cell lung cancer, providing further rationale for the utility of this combination therapy to treat metastatic foci in the lung (40, 41).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, T. J., Khatcheressian, J. L., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,634
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,370
Self-citationReview of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 698
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Schoenfeld, D., & Richter, J. R. (1982) · Biometrics · doi:10.2307/2530299 · Cited by 356
Girling, D. J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)02005-3 · Cited by 224
Souhami, R. L., Spiro, S. G., Rudd, R., de Elvira, M. C. R., James, L. E., Gower, N. H., Lamont, A., & Harper, P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.8.577 · Cited by 202
Niell, H. B., Herndon, J. E., Miller, A. A., Watson, D. M., Sandler, A. B., Kelly, K. L., Marks, R. S., Perry, M. C., Ansari, R., Otterson, G. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.071 · Cited by 187
Timmer-Bonte, J. N. H., BOO, T. M. D., Smit, H. J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7955 · Cited by 185
Toxicity Grading Criteria of the Japan Clinical Oncology Group
Tobinai, K., Kohno, A., Shimada, Y., Watanabe, T., Tamura, T., Takeyama, K., Narabayashi, M., Fukutomi, T., Kondo, H., Shimoyama, M., et al. (1993) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039642 · Cited by 168
Self-citationInfluence of age on the treatment of limited-stage small-cell lung cancer.
Siu, L. L., Shepherd, F. A., Murray, N., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.821 · Cited by 139
Okamoto, H., Watanabe, K., Nishiwaki, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3540 · Cited by 91
Self-citationArdizzoni, A., Favaretto, A. G., Boni, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.140 · Cited by 90
Murray, N., Grafton, C., Shah, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3323 · Cited by 88
Findlay, M., Griffin, A.-M., Raghavan, D., et al. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90422-a · Cited by 73
Maksymiuk, A. W., Jett, J. R., Earle, J. D., Su, J., Diegert, F. A., Mailliard, J. A., Kardinal, C. G., Krook, J. E., Veeder, M. H., & Wiesenfeld, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.70 · Cited by 71
Oral Etoposide and Carboplatin
Evans, W. K., Radwi, A., Tomiak, E. M., et al. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00011 · Cited by 69
Westeel, V., Murray, N., Gelmon, K. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1940 · Cited by 64
Morita, T. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01195.x · Cited by 60
Radford, J. A., Ryder, W. D. J., Dodwell, D., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90581-y · Cited by 59
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer
Matsui, K., Masuda, N., Fukuoka, M., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.325 · Cited by 56
Quoix, É., Breton, J.-L., Daniel, C., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011171722175 · Cited by 56
A reverse transcriptase‐polymerase chain reaction assay in the diagnosis of soft tissue sarcomas
Naito, N., Kawai, A., Ouchida, M., Dan’ura, T., Morimoto, Y., Ozaki, T., Shimizu, K., & Inoue, H. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9 · Cited by 43
Larivé, S., Bombaron, P., Riou, R., et al. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00288-4 · Cited by 40
Okamoto, H., Naoki, K., Narita, Y., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.004 · Cited by 24
Self-citationSamantas, E., Skarlos, D. V., Pectasides, D., et al. (1999) · Lung Cancer · doi:10.1016/s0169-5002(98)00095-6 · Cited by 15
Carney, D. N. (1995) · Lung Cancer · doi:10.1016/s0169-5002(10)80021-2 · Cited by 15
Pfeiffer, P., Hansen, O., Rose, C., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.24.1892 · Cited by 8
Hotta, K., Harita, S., Bessho, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7063 · Cited by 8
Flagged first, then by citations
Cited by
Sorted by citations
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Metadata
- Authors
- on Behalf of the Japan Clinical Oncology Group (JCOG)-Lung Cancer Study Group, Okamoto, H., Watanabe, K., Kunikane, H., Yokoyama, A., Kudoh, S., Asakawa, T., Shibata, T., Kunitoh, H., Tamura, T., & Saijo, N.
- Affiliations
- Yokohama Municipal Citizen's Hospital (JP)
- Niigata Cancer Center Hospital (JP)
- Osaka City University (JP)
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Okamoto, H
- Venue
- British Journal of Cancer
- Published
- 2007-06-19
- Volume
- 97
- Issue
- 2
- Pages
- 162-169
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360311
- OpenAlex
- W2019041562
- Cited by
- 213
- References
- 30
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 11 · 2023: 13 · 2022: 15 · 2021: 17 · 2020: 10 · 2019: 9 · 2018: 16 · 2017: 16 · 2016: 11 · 2015: 6 · 2014: 7 · 2013: 20 · 2012: 12
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- extensive-stage small cell lung cancer, carboplatin, etoposide, cisplatin, elderly patients, poor-risk patients, chemotherapy toxicity, neutropenia, overall survival, response rate, palliative care, granulocyte colony-stimulating factor
- MeSH terms
- Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Treatment Outcome, Carcinoma, Small Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
